Colliers Securities Initiates Omnicell(OMCL.US) With Buy Rating, Announces Target Price $52
Omnicell Is Maintained at Neutral by JP Morgan
Omnicell Analyst Ratings
J.P. Morgan Maintains Omnicell(OMCL.US) With Hold Rating, Raises Target Price to $44
BofA Securities Maintains Omnicell(OMCL.US) With Hold Rating, Cuts Target Price to $54
BofA Securities Downgrades Omnicell(OMCL.US) to Hold Rating, Raises Target Price to $57
Omnicell Price Target Raised to $58.00/Share From $39.00 by Barclays
Omnicell Is Maintained at Buy by Craig-Hallum
Benchmark Co. Maintains Omnicell(OMCL.US) With Buy Rating, Raises Target Price to $62
A Quick Look at Today's Ratings for Omnicell(OMCL.US), With a Forecast Between $49 to $58
Omnicell Analyst Ratings
B of A Securities Downgrades Omnicell to Neutral, Raises Price Target to $57
Craig-Hallum Maintains Omnicell(OMCL.US) With Buy Rating
Wells Fargo Maintains Omnicell(OMCL.US) With Hold Rating, Raises Target Price to $41
Omnicell Is Maintained at Equal-Weight by Wells Fargo
Omnicell: A Hold Rating With a Cautiously Optimistic Long-Term Outlook
Omnicell Analyst Ratings
Benchmark Co. Maintains Omnicell(OMCL.US) With Buy Rating, Raises Target Price to $48
Analysts Are Bullish on Top Healthcare Stocks: Pulmonx (LUNG), Omnicell (OMCL)
Hold Rating on Omnicell Amid Modest Growth Prospects and Uncertain Sales Trajectory